Navigation Links
Onyx Pharmaceuticals Reports Third Quarter 2011 Financial Results
Date:11/2/2011

to regorafenib, a late-stage oncology compound. 

On a GAAP basis, Onyx reported a net loss of $36.9 million, or $0.58 per diluted share, for the third quarter 2011 compared to a net income of $41.5 million, or $0.66 per diluted share, for the same period in 2010. A description of the non-GAAP calculations and reconciliation to comparable GAAP measures is provided in the accompanying table entitled "Reconciliation of GAAP to Non-GAAP Net Income (Loss)."

Revenue from Collaboration AgreementGlobal Nexavar net sales, which are recorded by Onyx's collaborator, Bayer, were $250.3 million for the third quarter 2011, an increase of $24.1 million, or 11%, compared to $226.2 million for the same period in 2010. Onyx and Bayer are marketing and developing Nexavar® (sorafenib) tablets, an anticancer therapy currently approved for the treatment of unresectable liver cancer and advanced kidney cancer in over 100 countries worldwide.

For the third quarter 2011, Onyx reported total revenue from collaboration agreement of $75.0 million compared to $63.7 million for the same period in 2010.

License RevenueIn the third quarter 2010, Onyx recorded license revenue of $59.2 million, reflecting a fee earned as a part of the consideration under the September 2010 exclusive license agreement with Ono Pharmaceutical Co., Ltd.

Operating ExpensesOnyx recorded research and development expenses of $58.5 million in the third quarter 2011 compared to $44.6 million for the same period in 2010. The increase in research and development expense was primarily due to investments in the development of carfilzomib, particularly the Phase 3 ASPIRE and FOCUS trials as well as increased investment in the manufacturing of carfilzomib.  

Selling, general and administrative expenses were $42.6 million in the third quarter 2011, compared to $25.9 million for the same period in 2010. Higher selling, general and administrative
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 2015 Research and Markets ... of the "Lab Accessories Market by ... Station) & End User (OEM/Biotechnology & Pharmaceutical ... 2020" report to their offering. ... expected to reach $504.7 million by 2020 ...
(Date:4/24/2015)... Company, Inc. (NYSE: LCI ) today announced that ... facility to $120 million from $50 million.  The amended ... company to increase borrowings by a total of up ... commitments from existing lenders or new lending institutions.  The ... 2018.   "The amended credit facility, together ...
(Date:4/23/2015)... CHICAGO, Ill. , April 24, 2015  AbbVie ... Food and Drug Administration (FDA) has accepted its New ... company,s, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, ... for the treatment of adults with chronic genotype 4 ... regimen is the first all-oral, interferon-free therapy being evaluated ...
Breaking Medicine Technology:Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 2Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 3Lannett Expands Revolving Credit Facility To $120 Million 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7
(Date:4/24/2015)... The first step to transforming one’s ... For meditation and yoga teacher Stine Koppernæs, meditation and ... tools that allow her to experience more peace and ... a teacher since 2006, and through the years she ... being. , “I love sharing this way of finding ...
(Date:4/24/2015)... Carinsurancequotesinfo.com has released a new blog ... to qualify for auto insurance as a ... auto insurance online, without having to follow a special ... parents can reduce their auto insurance expenses. The tips ... explained. , Clients can now visit an insurance ...
(Date:4/24/2015)... Integrative Therapeutics has introduced two new supplements ... , A unique combination of herbs and nutrients, ... Complex apart from other antioxidant supplements. This formula ... antioxidation versus the use of single or sequential ... Resveratrol, Alpha-Glycosyl Isoquercitrin, and Coenzyme Q10 with Setria® ...
(Date:4/24/2015)... Orlando, Fla. (PRWEB) April 24, 2015 ... extraordinary healer” were among the ways Denise Weiner described ... Angeles, who cared for her daughter, Alexa, during her ... radiation, brain resections, a bone marrow transplant and numerous ... the house to visit Alexa when she was not ...
(Date:4/24/2015)... 2015 Insuranceautoquote.info has released a new ... premiums . , Lowering auto insurance prices is ... simply find better offers for their financial budget. Comparing ... does not require any registration. , Comparing quotes ... are multiple agencies that sell coverage and this means ...
Breaking Medicine News(10 mins):Health News:Auto Insurance Discounts for Single Parents - How to Qualify for Low Rates 2Health News:Integrative Therapeutics Introduces Two ProThrivers™ Wellness Supplements with Specialty Ingredients from Kyowa Hakko USA 2Health News:Integrative Therapeutics Introduces Two ProThrivers™ Wellness Supplements with Specialty Ingredients from Kyowa Hakko USA 3Health News:Integrative Therapeutics Introduces Two ProThrivers™ Wellness Supplements with Specialty Ingredients from Kyowa Hakko USA 4Health News:CURE™ Magazine Names Pediatric Nurse Laura Vasquez from Children’s Hospital Los Angeles As Extraordinary Healer™ of 2015 2Health News:CURE™ Magazine Names Pediatric Nurse Laura Vasquez from Children’s Hospital Los Angeles As Extraordinary Healer™ of 2015 3Health News:CURE™ Magazine Names Pediatric Nurse Laura Vasquez from Children’s Hospital Los Angeles As Extraordinary Healer™ of 2015 4Health News:Car Insurance Quotes Can Help Drivers Lower Their Premiums 2
... June 23, 2009 With millions of people in the ... and our Canadian neighbors doing likewise for their July 1 ... shows of the future likely to ignite a smile on ... is quietly making its way toward the sky. ...
... HIV/AIDS Atlas , , WASHINGTON, June 22 ... HIV/AIDS Atlas ( http://www.MapHIV.org ) that highlights the impact ... States. The Atlas makes information on HIV/AIDS prevalence ... time, painting a comprehensive picture of the varying intensity ...
... Quality Forum Launches First U.S. HIV/AIDS Atlas , , ... launched a groundbreaking HIV/AIDS Atlas ( http://www.MapHIV.org ... in communities across the United States. The Atlas makes ... for the first time, painting a comprehensive picture of the ...
... Economy! It,s the Perfect Time for Fitness! , , LOS ... or stair climber in the park or along the beach. Now ... putting the traditional fitness equipment on wheels, but with a unique ... Pumgo Fitness Scooter, a new concept of fitness, will be introduced ...
... Biomodels CRO expertise in $1 billion market for cancer ... , , WATERTOWN, Mass., June 22 Biomodels ... care, today announced that its customized research program allowed ... attain Food and Drug Administration (FDA) approval for Phase ...
... in the Bone Graft Market , , MOUNTAIN VIEW, ... bone graft market, Frost & Sullivan recognizes Bone Solutions, Inc. ... Technology Leadership of the Year for its development of OsteoCrete(TM). ... and tendons to bone and bone-to-bone. On May 21, ...
Cached Medicine News:Health News:'Green' fireworks may brighten eco-friendly 4th of July displays in future 2Health News:MapHIV.org Shows Six Counties in Louisiana Seriously Impacted by AIDS 2Health News:MapHIV.org Shows Six Counties in Louisiana Seriously Impacted by AIDS 3Health News:MapHIV.org Shows California's San Francisco County Seriously Impacted by HIV 2Health News:MapHIV.org Shows California's San Francisco County Seriously Impacted by HIV 3Health News:Pumgo Fitness Scooter Will Highlight Venice Beach This Summer 2Health News:Biomodels' Oral Mucositis Expertise Speeds FDA Approval for ActoGeniX's Phase 1b Trial of AGO13 in Cancer Patients 2Health News:Frost & Sullivan Selects Bone Solutions for Technology Leadership of the Year Award 2Health News:Frost & Sullivan Selects Bone Solutions for Technology Leadership of the Year Award 3Health News:Frost & Sullivan Selects Bone Solutions for Technology Leadership of the Year Award 4
... have proven that the management of diabetes in ... levels is the most effective way to reduce ... aimed at maintaining or improving a diabetes patients ... costly. , ,These have been the guiding ...
... about insulin dosages and other medication, about ... by data from blood glucose tests and ... that can be seen by you and ... is presented in organized and graphical formats. ...
... Green Photocoagulator - Portable and rugged solid-state ... clinic, and operating room. Built to high-duty ... the most demanding environments, the Novus Verdi ... A full line of accessories for private ...
The ring maintains the bag tension avoiding the development of posterior capsule pleats. It is also established to compensate the efforts induced during the bag retraction....
Medicine Products: